Archives Journalières: août 19, 2009

Maxime Moulard is CSO for BioCytex, a company that develops quantitative flow cytometry application kits. BioCytex is performing R&D and clinical investigations for major worldwide pharmaceutical companies. Biocytex is currently involved in developing diagnostic tools that can be used in a large spectrum of diseases including cancer, inflammatory diseases and hemostasis. Maxime has been involved in establishing and managing major corporate collaborations and partnerships (Eli Lilly, Sanofi-Aventis) as well as numerous academic and Institutional collaborations.
Prior to joining BioCytex in 2001, he was Visiting Scientist at The Scripps Research Institute (TSRI), in La Jolla, from 1998 to 2000. His scientific interests led him to develop new methods to generate and characterize human monoclonal antibodies using phage-display technologies. He received his Ph.D. in Biochemistry from the University Pierre & Marie Curie (Paris, France) and completed his post-doctoral training at the Institute für Virology in Marburg, Germany. He has published over 30 original manuscripts, book chapters, patents and reviews and has been a regular contributor of original research to the field of protein interaction and signaling mechanisms.

Valérie Philippon, Director of Publication Strategy and Management at Vertex

Valérie Philippon is the Director of Publication Strategy and Management at Vertex Pharmaceuticals, a company based in Cambridge, MA that is seeking to transform the way serous diseases are treated. She is responsible for the development and execution of Publication Strategy for Vertex HCV franchise. Valérie has over 15 years of experience in Research, Development, Program & Portfolio Management, Medical Writing and Publication Planning. She received her Ph.D. in Microbiology from the University of Paris, France where she studied the molecular pathogenesis of retroviruses. She continued in research doing a post-doctoral fellowship at Harvard School of Public Health under the direction of Dr Max Essex and studying the role of Vpr and Vpx proteins in HIV and SIV pathogenesis. Following the completion of her fellowship she accepted a scientist position at Therion Biologics where, as a scientist and program manager, she participated in the discovery and development of cancer immunotherapies and was responsible for the company HIV vaccine development. She then joined Idenix Pharmaceuticals as a Medical Writer where her responsibilities extended from helping clinicians and scientists to write abstracts, conference presentations and manuscripts to coordinate publication planning for the company’s HBV, HCV and HIV drug candidates.